news
US begins monkeypox vaccine and therapeutic trials
US National Institutes of Health initiates trials to evaluate antiviral tecovirimat (TPOXX) and possibility of delivering Jynneos vaccine intradermally.
List view / Grid view
Bavarian Nordic
article
Monkeypox update – August 2022
In this article, EPR’s Hannah Balfour discusses the recent multi-country monkeypox outbreak, highlighting key developments in the international response.
news
Bavarian Nordic to supply EU Member States with monkeypox vaccine
Bavarian Nordic has announced it will supply 110,000 doses of its MVA-BN smallpox/monkeypox vaccine to the European Health Emergency Preparedness and Response Authority (HERA) over the coming months.
news
Bavarian Nordic signs supply contract for smallpox vaccine as monkeypox cases rise
The agreement between Bavarian Nordic and an undisclosed country aims to ensure sufficient supply of smallpox vaccine to meet the country’s requirements for vaccinating individuals at risk for monkeypox.
news
Johnson & Johnson to donate 200,000 vaccine regimens to curb Ebola outbreak
To prevent the spread of the Ebola virus in West Africa, Johnson & Johnson is donating vaccines for a WHO early access clinical programme.
article
Developing a preventive vaccine regimen to tackle Ebola
Earlier this year, Johnson & Johnson announced the first major regulatory approval of a vaccine developed by Janssen for the prevention of Ebola. Nikki Withers spoke with the Global Head of Vaccines, Johan Van Hoof, to discover what technologies were used and how they are now being leveraged to develop…
news
EMA gives positive opinion to investigational Ebola vaccine regimen
Developed by Janssen, the two-dose regimen has already been given to 60,000 patients and now has the positive opinion of the Committee for Medicinal Products for Human Use (CHMP).
news
FDA approves vaccine for smallpox and monkeypox
The Jynneos live, non-replicating vaccination for smallpox and monkeypox has been approved by the FDA for high-risk patients.
news
Positive Phase I results for preventive Ebola vaccine regimen
20 April 2016 | By Victoria White, Digital Content Producer
Data from a Phase I study of a preventive Ebola vaccine regimen suggest that the regimen was well-tolerated by healthy volunteers and immunogenic...
news
Bavarian Nordic initiates Phase 1 clinical trial of MVA-BN RSV vaccine
18 August 2015 | By Victoria White
Bavarian Nordic has initiated a Phase 1 clinical study of its MVA-BN vaccine candidate against respiratory syncytial virus (RSV)...
news
Oxford Vaccine Group initiates Phase 2 study of Ebola prime-boost vaccine regimen combining MVA-BN-Filo and Ad26.ZEBOV
15 July 2015 | By Victoria White
Oxford Vaccine Group has initiated a Phase 2 clinical study of the Ebola prime-boost vaccine regimen that combines MVA-BN-Filo with Ad26.ZEBOV...
news
Bavarian Nordic receives bulk order for Imvamune smallpox vaccine
7 July 2015 | By Victoria White
BARDA, a division of the US Department of Health & Human Services, has ordered a bulk supply of Bavarian Nordic’s Imvamune non-replicating smallpox vaccine...
news
EIB supports Bavarian Nordic’s development of Ebola and cancer vaccines
13 May 2015 | By Victoria White
EIB has reaffirmed its commitment to respond to the Ebola pandemic by providing a EUR 50m loan to Bavarian Nordic for accelerated development of a vaccine...
news
Bavarian Nordic announces positive results from pivotal Phase 3 study of IMVAMUNE smallpox vaccine
13 May 2015 | By Victoria White
Results from a Phase 3 study of the liquid-frozen formulation of IMVAMUNE support a Biologics License Application for US approval of the vaccine...
